Affordable Access

deepdyve-link
Publisher Website

Medical marijuana in pediatric oncology: A review of the evidence and implications for practice.

Authors
  • Ananth, Prasanna1
  • Reed-Weston, Anne2
  • Wolfe, Joanne1, 3
  • 1 Department of Pediatric Hematology/Oncology, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts.
  • 2 Columbia University College of Physicians and Surgeons, New York, New York.
  • 3 Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts.
Type
Published Article
Journal
Pediatric Blood & Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Feb 01, 2018
Volume
65
Issue
2
Identifiers
DOI: 10.1002/pbc.26826
PMID: 28926679
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Medical marijuana (MM) has become increasingly legal at the state level and accessible to children with serious illness. Pediatric patients with cancer may be particularly receptive to MM, given purported benefits in managing cancer-related symptoms. In this review, we examine the evidence for MM as a supportive care agent in pediatric oncology. We describe the current legal status of MM, mechanism of action, common formulations, and potential benefits versus risks for pediatric oncology patients. We offer suggestions for how providers might approach MM requests. Throughout, we comment on avenues for future investigation on this growing trend in supportive care. © 2017 Wiley Periodicals, Inc.

Report this publication

Statistics

Seen <100 times